Transarterial radioembolization for hepatocellular carcinoma: a review

Rodolfo Sacco1
Caterina Conte2
Emanuele Tumino1
Giuseppe Parisi1
Sara Marceglio3
Salvatore Metrangolo1
Roberto Eggenhoffner4
Giampaolo Bresci1
Giuseppe Cabibbo5
Luca Giacomelli4

1Department of Gastroenterology, Cisanello Hospital, Pisa, 2Endocrinology and Metabolic Diseases, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, 3Department of Engineering and Architecture, University of Trieste, Trieste, 4Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, Genova University, Genoa, 5Section of Gastroenterology, DIBIMIS, University of Palermo, Palermo, Italy

Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often associated with a not-completely favorable safety/efficacy ratio. Therefore, other treatment options appear necessary in clinical practice. Transarterial radioembolization has shown a promising efficacy in terms of disease control and is associated with a good safety profile. This review discusses the use of transarterial radioembolization in HCC, with a focus on the clinical aspects of this therapeutic strategy.

Keywords: hepatocellular carcinoma, transarterial radioembolization

Introduction

Hepatocellular carcinoma (HCC) remains a frequent and highly lethal type of cancer.1,2 According to the most recent data, the global incidence of HCC is still increasing, although it varies throughout the world; in 2013, 818,000 global deaths were caused by liver cancer, 9% more than that in 2010 (752,000 global deaths).3,4 The treatment for HCC is difficult and requires a multidisciplinary approach, whereby specialists in gastroenterology, hepatology, radiology, oncology, surgery, and others need to bring their expertise to provide patients with the best and most updated therapies.5 Transplantation and surgical removal of liver tumors represent the first-line therapy for HCC. Unfortunately, only 20%–30% of patients with HCC are good candidates for resection due to either multifocal unresectable tumors or their underlying chronic liver disease.6 Tumor ablation (such as injection of alcohol, acetic acid, microwaves, laser, cryoablation, and the most commonly used radiofrequency) has become a frequently used and extremely effective nonsurgical treatment that provides excellent local tumor control and favorable survival benefit; however, its use in larger tumors has been unsuccessful.

Transarterial chemoembolization (TACE) is the treatment of choice in larger and later staged tumors. TACE consists of intra-arterial infusion of a Lipiodol and a chemotherapeutic agent such as doxorubicin, followed by an injection of embolic material such as gelatin sponge particles or other agents.8 However, the association with some contraindications makes it difficult to draw any firm conclusion about the tolerability of this treatment approach.9 Therefore, other treatment options appear necessary in clinical practice.

Transarterial radioembolization (TARE) has shown a promising efficacy in terms of disease control and is associated with a good safety profile. This review discusses
the use of TARE in HCC, with a focus on the clinical aspects of this therapeutic strategy.

**TARE: an overview of basic principles**

TARE consists of the selective intra-arterial administration of microspheres loaded with a radioactive compound such as yttrium-90 or Lipiodol labeled with iodine or rhenium by means of a percutaneous access. Of note, TARE does not exert any macro-embolic effect; therefore, all the effects of the treatment depend solely on the radiation carried by the microspheres. Overall, a bulk of evidence supports the use of this technique in the treatment of primary and metastatic HCC and cholangiocarcinoma.

Two different types of microspheres are currently available: the glass-made TheraSphere® and the resin-made SirSpheres®. Although they differ in a number of characteristics, including size and number of injected microspheres, current evidence shows the substantial clinical efficacy of the two approaches. However, TheraSphere® has a low embolic power, with higher activity for each microsphere (2,500 Bq vs 50 Bq for Sir-Spheres®). Therefore, TheraSphere® is more suitable when the prevention of vascular stasis and reflux is crucial, while it may not be the ideal choice for the treatment of large lesions. On the other hand, Sir-Spheres® is characterized by a higher embolic power, thus making it suitable in cases of large lesions; however, slow injections and angiographic control are necessary with this approach.

From a technical point of view, radioembolization comprises several stages. The first stage is the identification, according to a multidisciplinary assessment, of potentially eligible patients. Then, a diagnostic angiography is performed in order to evaluate the vascular anatomy and establish the most appropriate site of access. At the same time, labeled macroaggregates of albumin (MAA) are injected; their diffusion is similar to that of radioembolization microspheres and therefore can be studied by means of single-photon emission computed tomography/computed tomography to predict the actual diffusion of TARE microspheres. Of note, this simulation of diffusion allows a prediction of response to TARE and therefore plays a crucial role in the selection of patients and in the personalization of treatment. The amount of yttrium-90 administered is then specifically calculated for each patient in order to achieve the desired activity. The use of dual-tracer 99m Te-MAA-99m Te-SC fusion single-photon emission computed tomography, an imaging tool that merges data on radioactivity distribution with physiologic liver mapping, further enhances tailoring of treatment. Finally, microspheres are injected by a catheter within four weeks since the first visit.

However, TARE is not without its complications. Adverse events can be either due to delivery of toxic effects to nontumor tissues or by problems during the placement and manipulation of the catheter. Reported complications include liver failure or radio-induced liver disease (incidence up to 4%), biliary problems (<10%), post-radioembolization syndrome (20%–55%), gastrointestinal problems (<5%), and radio-induced pneumonia (<1%). An appropriate selection of patients may exclude those at higher risk of reporting TARE-associated adverse events. Moreover, medical treatment with proton pump inhibitors, steroids, analgesics, and anti-emetics can prevent the onset or reduce the severity of the abovementioned symptoms.

**TARE in HCC: current clinical evidence**

The European Society of Medical Oncology defined TARE as a promising and suitable therapeutic option either as a "bridging" treatment or as the main therapy for patients who present diffuse intrahepatic tumor spread. In addition, the National Comprehensive Cancer Network recommends TARE for patients with unresectable disease due to inadequate hepatic reserve, poor performance status, comorbidities, or specific location and extension of the tumor. The National Cancer Institute states that this approach may be considered in selected patients with liver-confined HCC, who are not eligible for transplant or resection.

However, given its relatively recent introduction in clinical practice and the paucity of randomized phase III trials, more evidence on the use of TARE needs to be collected for a full evaluation of its benefits and risks. The use of TARE in different clinical situations is discussed in the following sections.

**Early-stage HCC**

Liver transplant remains the elective approach for patients with early-stage (according to the Barcelona Clinic Liver Cancer [BCLC]-A classification) HCC. However, given the paucity of donors, patients often experience disease progression while on the waiting list, and therefore "bridging therapies" are often used to delay progression. TARE has been recently proposed in this setting, but to date specific evidence remains scant, and procedural costs are high.

**Intermediate-stage HCC**

Patients classified as having intermediate-stage (BCLC-B) HCC present very heterogeneous characteristics.
elective treatment is TACE, but its use is often not feasible due to several contraindications.

TARE may represent a suitable approach in this setting, thanks to its overall favorable safety profile. Although no head-to-head prospective study versus TACE is available, the use of TARE has been investigated in a number of retrospective studies. TARE is more expensive than TACE; however, this latter technique requires multiple procedures and is more often associated with adverse events, therefore increasing the overall expense.

In a study comparing 123 patients assigned to TARE and 122 receiving TACE, the former approach was associated with longer time to progression (13.3 months vs 8.4 months; \( P=0.046 \)) and less incidence of complications; however, no difference in overall survival (OS) was reported.43 These findings are in line with those reported in other studies.44–46 In a recent study, TARE was also associated with a lower need of hospitalization, when compared with TACE.47 Moreover, TARE showed a similar efficacy—in terms of survival—as sorafenib, which is the only medical treatment currently available for HCC and is also effective in patients with BCLC-B disease.48

In selected subjects with intermediate-stage HCC, tumor shrinkage is sometimes feasible in order to reduce disease burden and allow resectability or transplantation.49 In a retrospective study, TARE and TACE were compared in terms of percentage of tumor shrinkage, with TARE showing the better outcomes (−58% vs −31%; \( P=0.023 \)).50

We feel that the possibility of effective tumor downsizing in selected patients widens the opportunities for the use of TARE. In addition, this technique can be suitable for patients with large extent of disease and modest residual liver volume. In this subpopulation of BCLC-B patients, TARE can induce hypotrophy of the treated hepatic lobe, and therefore hyper-trophy of the contralateral lobe thus allowing surgery.51,52

**Advanced-stage HCC**

Sorafenib represents the elective treatment for patients affected from advanced-stage (BCLC-C) disease.53–56 In this setting, TARE has been associated with an OS of 6–10 months,56 lower than the results reported with sorafenib in clinical practice suggesting that TARE may be used in the treatment of patients who do not respond or are contraindicated to sorafenib treatment. In a recent small Spanish observational study on patients with HCC and portal vein invasion, treatment with TARE may be associated with a more prolonged survival compared with sorafenib.57 However, other studies are necessary to better elucidate the potential alternative role of TARE in the treatment of BCLC-C HCC.

According to the preliminary results of the European randomized SORAMIC trial, TARE followed by sorafenib appears as well tolerated as sorafenib alone.58 In more detail, the number of total (196 vs 222) and grade ≥3 (43 vs 47) adverse events was similar in combination treatment and control arms, respectively. Moreover, the spectrum of adverse events was similar in the two groups.

Selection of patients does play a role also in the use of TARE for BCLC-C HCC. It has been shown that patients with portal vein thrombosis involving segmental or lobar branches treated with TARE achieve an OS of up to 23.2 months.59,60 On the other hand, patients with portal vein thrombosis of the common portal trunk or with distant metastases achieve much poorer outcomes, with OS often shorter than 6 months.19,61

**Conclusion and perspectives**

According to available evidence, TARE represents a feasible and promising therapy for the treatment of all stages of HCC. However, given the relative paucity of evidence on the use of TARE in HCC, the conduction of clinical trials on this approach will be of utmost importance in the upcoming years.

To this end, the proper evaluation of clinical outcomes associated with TARE becomes crucial. At present, the efficacy of this technique is usually assessed by measuring changes in tumor markers or by radiological findings.62,63 However, tumor markers are often not specific and may fail in providing well-grounded clinical indications.64 The use of adequate evaluation criteria, such as the mRECIST criteria, can enhance accuracy.65,66 Of note, tumor necrosis determined by TARE is often irregular in distribution and contrast enhancement; therefore, the use of volumetric measurements of tumor necrosis has been proposed for the early identification of responders.67,68 These evaluation approaches will allow a more comprehensive evaluation of TARE pros and cons in the upcoming years.

**Acknowledgments**

Editorial assistance for the preparation of this manuscript was provided by Sara Parodi, PhD; this assistance was supported by internal funds.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


25. SirTex Medical. IR-Spheres® Training Program: Physicians and Institutions. Lane Cove: SirTex Medical.


